What is semaglutide?
Semaglutide copies GLP-1, the fullness hormone your gut releases after eating — slowing digestion, quieting appetite, and steadying blood sugar. It's one of the most-studied molecules in modern metabolic medicine.
These articles cover it from every angle: mechanism, dosing, side effects, results measured in trials, and how compounded semaglutide differs from brand-name versions. It's prescription-only through Promise: a licensed provider reviews every request, and not everyone qualifies. If you're starting from zero, begin with the mechanism article — the rest makes more sense once the hormone story is clear.
96 articles on this topic
-
Interstate Medical Licensure Compact Guide
The compact can speed a physician's path to licenses in multiple states, but each license still belongs to one state—and the patient's location still controls the telehealth check.
-
How to Check If a Telehealth Doctor Is Licensed
A license check takes only a few minutes when you use the right source. Start with the clinician's legal name, verify current authority in the state where you will attend the visit, and treat an NPI as a cross-check—not a license.
-
Semaglutide Cost: Brand, Self-Pay and Compounded
Wegovy lists near $1,350 a month and Ozempic near $1,040, while the manufacturer's own self-pay channel charges $349 and eligible Medicare beneficiaries now pay a $50 copay. Same molecule, four very different bills.
-
Semaglutide for Type 2 Diabetes: What Trials Show
Brand semaglutide is approved for glycemic control in adults with type 2 diabetes, and the trial record now runs past blood sugar into heart and kidney outcomes. Compounded semaglutide is a different thing again — here is what separates them.
-
How Long Does Semaglutide Stay in Your System?
Injectable semaglutide has an elimination half-life of about one week and can remain in circulation for roughly five to seven weeks after the last dose. Its effects fade on a curve, not at a single cutoff.
-
How to Inject Semaglutide Safely
Semaglutide goes into the fatty layer beneath the skin of the abdomen, front of the thigh, or back of the upper arm. The device and pharmacy label—not a generic online diagram—determine the exact technique and measured amount.
-
Microdosing Semaglutide: What the Evidence Says
A slower climb can be a tolerability strategy. Staying indefinitely on a fraction of a studied dose is a different idea, and the evidence for it is not there yet.
-
How Does Semaglutide Work? Four Effects Explained
Semaglutide activates one receptor but produces coordinated signals in the pancreas, stomach and brain. Its engineered C18 side chain keeps those signals available for about a week.
-
Semaglutide Brand Names: Ozempic, Wegovy, Rybelsus
Ozempic, Wegovy, and Rybelsus all contain semaglutide, but their approved uses and formats differ. Compounded semaglutide is not a brand or generic.
-
How to Get Semaglutide Prescribed
You can get semaglutide through primary care, a specialist clinic, licensed telehealth or a manufacturer-supported route. Every legitimate path requires medical review before a pharmacy dispenses it.
-
Compounded Semaglutide: What It Is in 2026
Compounded semaglutide is a patient-specific prescription, not a generic Ozempic or Wegovy. The ingredient form, dosing label, and post-shortage rules all matter.
-
Semaglutide Pill vs Injection: What Exists
There is a semaglutide pill. There is no tirzepatide pill, and there is unlikely to be one. Understanding why comes down to what happens to a 39-amino-acid peptide in your stomach.
-
Semaglutide Dosage: The 17-Week Ladder
The Wegovy injection schedule for weight management climbs through five doses over sixteen weeks before reaching 2.4 mg. That deliberate pace is the single best-supported way to make the first months tolerable.
-
Semaglutide Side Effects, From Common to Rare
Across pooled STEP-trial safety data, only 4.3% of adults taking semaglutide 2.4 mg stopped treatment because of gastrointestinal side effects.
-
Tirzepatide vs Semaglutide: The Head-to-Head Data
In the SURMOUNT-5 trial, adults with obesity but without diabetes averaged 20.2% body-weight loss on tirzepatide and 13.7% on semaglutide over 72 weeks.
-
Semaglutide Weight Loss Results: 14.9% in 68 Weeks
Adults with obesity in the 68-week STEP 1 trial lost an average of 14.9% of their body weight on weekly semaglutide, while the placebo group averaged 2.4%.
Page 5 of 5 · 96 articles